Noob Investor

Chemist by Education | Banker by Profession
Investor/Photographer by Passion E-mail - [email protected]

[Noob Investor @ar9abN]

Signing off from PF disclosures before SEBI signs into my DMs.
Thanks to my friends' legal paranoia, this is the last one.
Going forward, only stock research...the portfolio will remain a mystery 🫡

𝐚𝐜𝐡𝐚 𝐜𝐡𝐚𝐥𝐭𝐚 𝐡𝐮 𝐝𝐮𝐚𝐨 𝐦𝐞 𝐲𝐚𝐚𝐝 𝐫𝐚𝐤𝐡𝐧𝐚 😭

[abhay jain @abhayjainp]

Growth Triggers for Indo-MIM.

World's largest MIM manufacturer, 6.8% global market share. No listed peer in India.

portfolio of more than 9,000 Products.

Makes turbine engine castings through investment casting.

gas turbine makers booked for years on data centre power demand, castings are the bottleneck.

Foldable hinge JV with a South Korean partner.

Backward integrating into metal powder, a key raw material for MIM.

Can do around 870cr PAT by FY29 (my estimates)

[Aquila SME @AquilaSME]

#DevsonCatalyst uploaded it's First PPT post IPO 🧪

~ Current Capacity - 6205 MTPA - running at 87%

~ Post Expansion capacity - 11,293 MTPA 👏

🔹Business Understanding 👇

India is entering a massive industrial capex cycle.

Every refinery cannot simply buy catalysts from anyone.

🔹Products must go through

✔ Vendor approvals

✔ Process validation

✔ Technical qualification

✔ Performance testing

✔ Trial runs

This creates very high switching costs.
Once approved, customers usually stay for years.

That is one of Devson's biggest moats.

🔹The end markets are expanding rapidly:

• Refining capacity: 256.8 → 300 MMTPA by 2028
• Petrochemical capacity: 29.6 → 46 MT by 2030
• LNG regasification: 52.7 → 66.7 MMTPA
• Hydrogen production: 10.5 → 17 MMTPA
• Fertilizer output: 503 → 600 LMT
• Auto production: 3.1 → 5 Cr vehicles

🔹Devson doesn't produce steel fertilizer petrochemicals or hydrogen.

Instead,
it supplies the critical components that ALL these industries require.

As these sectors expand, Devson benefits.
Hence, a PROXY Player

Key investment takeaway 🌟

#Devson Catalyst isn't selling a discretionary product.

It manufactures mission-critical industrial consumables that help billion-dollar plants run efficiently, safely, and within environmental norms.

With high customer qualification barriers, repeat business, strong return ratios, planned capacity expansion, and structural demand drivers from refining, chemicals, natural gas, and hydrogen, it operates in a niche where sustained industrial capex can translate into long-term growth. 👏

[Luxi ⭐ @0xLuxi]

Me trying to trade like a whale with a $500 portfolio 😭

[The Cloaked Gaze 👀 @gaze_observer]

Pine Labs Limited Q1FY27 Results:-
#Q1Results #Q1FY27 #Stockmarket #Nifty #Pinelabs

➤ Revenue ₹737 Cr (+20% YoY)

➤ Contribution Margin ₹533 Cr (72.3% Margin)

➤ Adjusted EBITDA ₹126 Cr (17.1% Margin)

➤ PAT ₹20 Cr (4x YoY vs ₹5 Cr in Q1 FY26)

➤ Platform GTV ₹4.22 Lakh Cr (~$45 Bn)

➤ Transactions Processed 201 Cr

➤ Digital Checkout Points 21.7 Lakh (+18% YoY)

➤ Merchant Base 11.5 Lakh

➤ Merchant digitization continued to accelerate, with strong adoption of UPI-first, screen-based checkout solutions among enterprise and mid-market merchants

➤ Instore & Flow services delivered robust growth, with Flow GTV +54% YoY, UPI GTV +80% YoY, and DCC GTV +40% YoY

➤ Added 40+ new online merchants across quick commerce, e-commerce, travel, and enterprise segments

➤ International revenue grew 21% YoY to ₹114 Cr, with continued expansion across 22 countries

➤ Expanded Issuing (IAP) platform with new consumer categories, including gaming, employee benefits, wallets, and expense management solutions

➤ Launched P3P, India's first Agentic Payment Protocol, built with Grantex

➤ Introduced Credit Line on UPI, enabling bank-issued credit directly through consumers' UPI IDs, expanding UPI beyond debit-only payments

➤ Continued investments in AI and next-generation commerce architecture, positioning Pine Labs to build the intelligence and credit layer on top of India's public digital payments infrastructure

[STR @sachprat07]

#C2C #C2C #C2CAdvancedSystems

C2C Advanced Systems Investor Call Highlights

👉 FY27 & Future Outlook:
▫️ Focus on collections completion by Sept 2026 (minimum 80% of receivables outstanding beyond vanity days;
💠~20 Cr incoming by 31 Jul, 60-75 Cr in Aug, further ~50 Cr by 30 Sept; some warranty retention of 8-15% standard).
💠Post-Sept collections, dedicated strategy/growth roadmap session planned after AGM.
💠 Intent to publish collection progress every 20 days; address investors before 31 Aug (prior to AGM); hold investor calls every 3 months; release quarterly results after 2026-27 accounting year.

▫️ Building C2C Innovation and Research Centre (CIRC) – foundation laid for internal innovation + ecosystem with entrepreneurial innovators and institutions (IITs etc.); aim in 10 years to become India’s leading innovation engine.
💠 Magi C5 ISR platform validated by demanding global sovereign clients; building Magi OI/OS AI/ML layer for sensor-integrated autonomous systems (pioneer space requiring defence domain + advanced software; not commercial AI competition).
💠 Overseas margins far higher than India (India net margins not expected to exceed ~25%; overseas often 2x+ pricing vs India quotes, strong payment/tech respect).

▫️Global environment “very hot”; good position in SE Asia (at least 3 countries) on G2G deals.
💠Selective order intake – turning down high-risk (>180 days) or low-margin (e.g., NCNC) contracts, including some prestigious Indian projects. Indian defence contracts expected <20% over next 2 years.
💠 Dubai Experience Centre operational (equipment/facility in place; minor connectivity pending; demonstrations ongoing; relationship with up-and-coming Abu Dhabi defence company).
💠 Platform repeatability high (core ontology/superset standard; minimal engineering tweaks for sensors/configs); counter-drone and other systems already repeating with improving payment terms domestically and overseas.
💠License revenue ~10% of total (FY26 ~5-6 Cr). Aim for higher free cash flow visibility by mid-2027.

👉 Current order book / projects and future pipeline:
▫️ Disclosed contracts close to ~100 Cr given to stock exchange
💠Copy of orders shared; names confidential for national security. Two out of six major receivables already completed payments; balance clearing Aug-Sept.

▫️Healthy pipeline of qualified opportunities across SE Asia, Middle East, Europe, USA (sensitive sovereign clients; disclose only at materiality threshold).
💠Over 1,000 Cr+ potential bids (actual higher; some may not be taken); includes sole-bidder / one-of-two-bidder positions and nominated-vendor status with MoD for strategic systems (trials completed over ~2 years; government returns for requirements).
💠 Recent/ongoing: Combat management system for Royal Malaysian Navy; counter-drone systems (Tier-1 India + global; ~80 Cr drone order – bank-guarantee-linked cash expected Sept/Oct)

▫️Navigational platform (sole vendor); white-labelled Decision Support System license + computing systems to North American market (major breakthrough); industrial IIOT/proprietary projects (e.g., CRI Pumps significant effort, larger orders anticipated; POCs often preliminary to bigger contracts).
💠 Geographic bases established in SE Asia, Mideast, USA; entering Europe via Romania. Magi-C5 ISR (sensors/seekers/data/comms integration – agnostic to legacy/modern/emerging sensors; dual-use Defence/Homeland Security/Critical Infrastructure/Industry 5.0) is core – all systems derive from it. Also subsystems + full systems in C5ISR (incl. cyber).
💠 Industrial side: sensor fusion/command-control of diverse sensors (Honeywell/Allen-Bradley etc.) for Industry 3.0→4.0→5.0; Defence: nominated for strategic systems not widely available.
💠 One client (technology partner post-Israeli refusal): command-control systems; short payment terms; every sale includes C2C tech. Emergency procurement opportunities progressing (part of larger pipeline).
💠Sole-source tech/software-intensive projects (e.g., IDEX-style logic; 9-level approvals completed for some; MOQ expansion potential).

👉 Brief additional clarifications from call:
▫️Malaysian ~7 Mn sales invoiced from India (segmental classification queried – management to check auditors; sensitive security establishment delivery completed).

▫️ Industrial “POC” language in updates = preliminary contracts for larger clients; payments received for delivered work (not pure unpaid POC).

▫️ US branch is not subsidiary – US billing included in Indian revenues.

▫️Related-party promoter funding was risk capital to keep company standing (SEBI-reported)
💠Synergy Login receivables fully closed (accounting vs ICDR nuances disclosed in RHP).

▫️H2 FY26 revenue lower than some guidance expectations partly due to US branch billing + delivery/testing delays (tariffs, new-gen sensors, software upgrades); most post-31 Mar 2026 deliveries completed with written client confirmations.)

👉 Other notable points:
▫️ Krishna Chandra (ex-Chief Strategy Officer) appointed CEO reporting to Board (accepted post 18 Jul 2026 Board meeting).

💠 Audit 2025-26: Delays from IFRS-audited US branch financials (US auditor indisposed ~25 days; atypical vs US practice).
💠Not a qualified opinion / no going-concern conclusion – only conditional observation under SA-570 (receivables aging; resolved via client written confirmations reviewed by auditors). Impact of audit qualification = Nil.

▫️14 Cr (approx.) Expected Credit Loss (ECL) provision under IFRS 9 / Ind AS 109 (forward-looking; industry 4-5% norm; fully recoverable, no bad debts; reversible on collection; already starting to reverse).
💠Reduced H2 profit ~5.5 Cr due to interest provision on related-party transactions.
💠 Board approval to appoint Vasudeva & Vasudeva CA as consulting auditors (streamline processes/compliance) in preparation for Big-10 auditor from FY 2027-28.
💠 Every material collection to be intimated to exchange. Collections already ~25 Cr credited since 1 Apr (on track). Exchange-rate gains possible on some bills.
💠 Technology real, clients real, confirmations in hand, collections coming.
💠Mistakes acknowledged (late filing, receivables aging beyond thresholds) – not hidden.
💠Platform competes with global best (e.g., comparable logic to Anduril Lattice).

[Aman Godhasara @Aman81407075]

Title: Two Hospitals, One Address Each — What Happens When a Chain Has No Chain (KMC Speciality & Hannah Joseph)

Every name in this series so far has been racing to add cities, add clusters, add beds. This post is about the opposite bet — two hospitals that never left home. One is bursting at the seams. The other has half its beds empty on purpose. Here's why both stories matter.

THE TWO NAMES

KMC Speciality — a 450-bed multi-specialty hub in Trichy, Tamil Nadu, running at 76% occupancy. Hannah

Joseph Hospital — a 133-bed single-specialty center, running at just 43% occupancy — 57 beds occupied out of 133.

One hospital can barely fit another patient. The other has more empty beds than full ones. Same "single-location" category, completely opposite chapter of the story.

WHY SINGLE-LOCATION HOSPITALS ARE A DIFFERENT

Before the numbers, understand what you're actually underwriting when you own a standalone hospital instead of a chain like Yatharth, Park, Rainbow, or Unihealth:

→ Geographic concentration — 100% of revenue sits behind one address. If a competitor opens next door in Trichy or Madurai, or local regulation shifts, there's no other city's revenue to absorb the hit.

A multi-state chain like Park (5 states) or Rainbow (6 states) simply doesn't carry this exposure.

→ Key-doctor dependency — single-specialty hubs are often built around one legendary clinician. Hannah Joseph's neurosurgery program, for instance, is closely tied to Dr. M.J. Arunkumar.

If a star surgeon retires or moves, volumes can drop fast — chains hedge this with team-based consultant models and their own DNB training pipelines that manufacture the next generation of doctors in-house.

→ No hub-and-spoke — standalone hospitals have to win every patient directly. They don't have 5-8 feeder clinics in surrounding towns quietly funneling complex cases into their main OT, the way Rainbow's spoke network does.

→ Weaker procurement power — negotiating for an MRI, a robotic surgery system, or bulk pharma pricing is simply more expensive at 133 or 450 beds than at a 3,000+ bed network.

These aren't hypothetical risks — they're the trade-off standalone hospitals accept in exchange for something chains rarely get: total focus.

STORY ONE — KMC SPECIALITY: WHAT DO YOU DO WHEN THE HOSPITAL IS FULL?

FY26 numbers:
revenue ₹310.8 Cr (+32.5% YoY),
EBITDA ₹93.0 Cr (29.9% margin, +430 bps),
PAT ₹46.7 Cr — up 118.1% YoY,

more than doubling. That gap between 32% revenue growth and 118% profit growth is operating leverage doing exactly what it's supposed to do.

But here's the real puzzle:

occupancy is at 76% for the year, 81% in Q4. Above ~80%, a hospital is functionally full — beds need turnover time, sterilization, emergency buffer.

So how does a hospital that's basically out of empty beds keep growing revenue? Four levers, all visible in KMC's own numbers:

1) ARPOB expansion — replace routine cases with complex ones. KMC's blended ARPOB grew 16% YoY to ₹32,085/day (₹32,838 in Q4) — the hospital is making more from the same bed, not adding beds.

2) Cutting ALOS — a bed that turns over in 4 days instead of 5 treats meaningfully more patients a year. KMC took ALOS from 5.2 to 4.9 days, which is exactly how IPD volumes grew 18% YoY while census beds stayed flat at 330.

3) OPD & pharmacy growth — outpatients don't occupy a single inpatient bed but still pay consultation, lab, and pharmacy bills. KMC's OPD footfall surged 28% YoY to nearly 2 lakh visits, with outpatient ARPP up 10% to ₹2,716 — high-margin revenue with zero bed constraint.

4) Shifting the specialty mix upward — KMC's Bone Marrow Transplant (97+ completed) and Liver Transplant (44+ completed) programs carry far higher billing per patient, part of why inpatient ARPP grew 9% to ₹1,28,340.

STORY TWO — HANNAH JOSEPH: THE HEADROOM PLAY

FY26 revenue: ₹92.05 Cr,
EBITDA margin 27.12%,
revenue per bed per day around ₹38,000 — actually higher than Kauvery's own ARPOB, reflecting its specialty-heavy neuro and oncology case mix.

But the number that matters most here is occupancy: just 43%, or 57 of 133 beds filled.

That's not a red flag — it's the entire investment case.

A hospital running at less than half capacity, with a revenue-per-bed rate that's already premium, has room to roughly double patient volumes on infrastructure it's already built and already paid for.

No new land, no new construction, just fuller wards. And management isn't standing still while that headroom sits there — a dedicated Radiation Oncology campus is under construction on adjacent acquired land, adding a high-value specialty line right at the moment the hospital most needs one to pull in more complex, higher-billing cases.

Two hospitals, two completely different growth stories: Kauvery has to earn more from every bed because there are no more beds to give. Hannah Joseph just has to fill the ones it already has.

THE TAKEAWAY

Standalone hospitals trade geographic diversification for something real — higher regional margins, no corporate overhead drag, no distant-city gestation losses eating into returns.

Chains trade that focus for scale and risk-spreading. Neither is strictly better; they're just different bets on where the next leg of growth comes from.

Kauvery's bet is realization — squeezing more out of beds that are already full.

Hannah Joseph's bet is utilization — filling beds that are sitting empty. Watch which lever each pulls next, because that's what tells you whether the thesis is playing out.

This is not investment advice — just how I break these businesses down before deciding whether any of them earn a place in my portfolio. Always do your own research.

A hospital that's full vs. one that's half-empty on purpose — which setup would you rather own? Let me know below.

#hospital #stockmarket #smallcaps #indianequity

[Aditya Sharma @aditya_sh96]

https://t.co/WgossKUAze

[T-Rex @T_RexRoars]

Start these memes again 😂

[Darshan Mehta @darshanvmehta1]

RK Forging in focus

- Super guidance by management
- Revenue target of Rs 8000 cr by FY29 which is 20-25% CAGR
- Margins a 20% from 16% now
- ROCE of 12-15% for FY27, rising to ~20% in FY28
- Net debt reduced by ~100 crore QoQ to ~1,800 crore
- Targeted 500 crore leverage reduction for FY27
- CapEx guidance for the year is ~350 crore

[Yatin Mota @yatinmota]

Positive for CMPDI

The Union government has announced a ₹40,000 crore corpus for scientific mine closure

Along with a ₹40,000 crore corpus, the government signed an agreement with Germany's GIZ to strengthen scientific mine closure, land restoration, and post-mining development

https://t.co/eVTHlCDHBe

[VaR @Vedansh_Ag]

HIIL | Revenue doubles in FY27, then doubles again in FY28.

[KRISH @KYourhope57689]

Kavach + Signaling is huge market in coming 6-7 years in India. Almost 1+2, 3 lakh crore TAM.

Choose the right player and ride.

[R @AlphaWizarDD]

Every Indian retail investor has an Abhishek Kalra inside them.

Owns 1 share of GKB Lenses.

Shows up to the AGM. Lectures the management for 3 minutes straight like he's the largest shareholder.

We've all wanted to do this at least once.

[Dhanesh Gianani @dhanesh500]

Acha hua gaadi khareed li,

Warna itni baarish mein Mutual Funds mein baithke office jana padta

[Noob Investor @ar9abN]

@theMihirV The only two directors I blindly TRUST 😄

[Trader Theory @tradertheory]

Goldman Sachs trader Anton Kriel explains how professional traders ACTUALLY act:

[Noob Investor @ar9abN]

@boidawonda That's why i only dm whatever i read ...only to the trusted one's bass ...keep it simple 🫡

[Noob Investor @ar9abN]

@boidawonda @amurfalcon1 @Salman_2911 @IndraprasthaCap @TheScooper7 @alphaaInvestor Thank you bro 🫡

[Noob Investor @ar9abN]

@boidawonda @KYourhope57689

[lynk @lynk0x]

Me going to my job not to survive, but to fund my trading capital.